Terns Pharmaceuticals(US:TERN) Globenewswireยท2025-08-05 20:05Core Insights - Terns Pharmaceuticals is advancing its clinical programs with a focus on oncology and obesity, expecting key clinical readouts by year-end 2025 [2][3] - The company has a strong cash position, with sufficient funds to support operations into 2028 [7][10] Clinical Trials and Pipeline Developments - The Phase 1 trial of TERN-701 for chronic myeloid leukemia (CML) is enrolling well, with efficacy and safety data, including 6-month major molecular response (MMR) rates, expected in Q4 2025 [1][3] - The Phase 2 trial of TERN-601 for obesity has completed enrollment, with 12-week efficacy, safety, and tolerability data anticipated in early Q4 2025 [1][8] - Terns plans to report data from the Phase 1 CARDINAL trial of TERN-701 in Q4 2025, which will allow for comparisons with other CML treatments [2][3] Financial Performance - As of June 30, 2025, Terns reported cash, cash equivalents, and marketable securities of $315.4 million, down from $358.2 million at the end of 2024 [7][10] - Research and development expenses for Q2 2025 were $20.4 million, compared to $18.4 million in Q2 2024 [7][9] - The net loss for Q2 2025 was $24.1 million, slightly higher than the $22.7 million loss in Q2 2024 [9] Corporate Updates - Terns will host an educational webinar focused on TERN-701 in September 2025 [1][3] - Members of Terns' senior leadership will participate in the Morgan Stanley 23 Annual Global Healthcare Conference in September 2025 [7]